Compare · EPIX vs MEIP
EPIX vs MEIP
Side-by-side comparison of ESSA Pharma Inc. (EPIX) and MEI Pharma Inc. (MEIP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EPIX and MEIP operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MEIP is the larger of the two at $253.7M, about the same size as EPIX ($253.2M).
- Over the past year, EPIX is down 88.5% and MEIP is up 44.8% - MEIP leads by 133.3 points.
- Both have 5 recent analyst ratings on file.
- Company
- ESSA Pharma Inc.
- MEI Pharma Inc.
- Price
- $0.20-5.01%
- $3.06+9.50%
- Market cap
- $253.2M
- $253.7M
- 1M return
- -18.31%
- -37.14%
- 1Y return
- -88.51%
- +44.79%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2003
- News (4w)
- 0
- 0
- Recent ratings
- 5
- 5
ESSA Pharma Inc.
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.
MEI Pharma Inc.
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. The company has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and license agreements with Presage Biosciences, Inc. and CyDex Pharmaceuticals, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is headquartered in San Diego, California.
Latest EPIX
- SEC Form EFFECT filed by ESSA Pharma Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by ESSA Pharma Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by ESSA Pharma Inc.
- SEC Form 15-12G filed by ESSA Pharma Inc.
- President and CEO Parkinson David Ross returned 65,675 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Financial Officer Wood David S. returned 33,343 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Berger Franklin M returned 784,404 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Glickman Richard M returned 43,240 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Requadt Scott returned 30,002 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Martin John Alexander returned 14,299 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest MEIP
- MEI Pharma Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities
- New insider Schornstein Alexander claimed ownership of 4,365,472 shares (SEC Form 3)
- MEI Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker 'LITS'
- SEC Form EFFECT filed by MEI Pharma Inc.
- SEC Form 424B3 filed by MEI Pharma Inc.
- MEI Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Amendment: SEC Form S-3/A filed by MEI Pharma Inc.
- SEC Form 4 filed by Director Riezman Joshua
- SEC Form 3 filed by new insider Riezman Joshua